Arcellx surges after promising data from mid-stage cancer therapy trial

Arcellx

08/12/2025 11:40

** Shares of cancer therapy developer Arcellx ACLX.O jump 9.8% to $76.39 premarket

** Co announces positive mid-stage trial results for Anito-cel, an experimental cancer therapy for multiple myeloma, a type of blood cancer

** Therapy targets blood cancer that has relapsed and/or is not responding to treatment

** For 112 Of the 117 patients in the trial, the disease was responsive to the therapy, co says

** ACLX is up 1.6% YTD, up to last close

 (Reporting by Utkarsh Tushar Hathi in Bengaluru)

 ((utkarshtushar.hathi@thomsonreuters.com))